MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1021/acs.analchem.5c06531

Медицинская библиотека · Analytical chemistry · 2026

Polyclonal Antibody Therapeutics: Analytical Innovations and Regulatory Perspectives for Addressing Heterogeneity Challenges.

Kumar Sunil, Tini Aurora, Tengattini Sara, Rinaldi Francesca, Calleri Enrica, Massolini Gabriella, Temporini Caterina

СтатьяОбзорПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Polyclonal antibodies (pAbs) are a cornerstone of the adaptive immune system, providing broad-spectrum protection by recognizing and neutralizing diverse antigens. Intravenous immunoglobulins (IVIg) derived from animal/human plasma are widely used to treat diseases such as primary immunodeficiencies, autoimmune neurological disorders, and situations requiring rapid immune protection, such as emerging infectious disease outbreaks. Compared with monoclonal antibodies (mAbs), pAbs offer several advantages, including faster, less technically demanding, and more cost-effective production, often directly from immunized animals or human serum. However, their complex, heterogeneous nature─reflecting the polyclonal response to multiple epitopes─creates significant challenges for characterization, quality control, and regulatory approval. pAbs have been underutilized in therapeutic applications due to the absence of robust, standardized analytical tools capable of fully assessing their heterogeneity. Conventional chromatographic and spectroscopic methods yield limited qualitative and quantitative information, insufficient for detailed structural and functional evaluation. This perspective highlights recent advances in high-resolution analytical technologies, particularly chromatographic and mass spectrometric approaches, that enable in-depth characterization of critical quality attributes (CQAs) of pAbs. These analytical strategies facilitate the assessment of parameters such as structural integrity, molecular size distribution, subclass composition, and polyclonality, which are crucial for ensuring product quality. Alongside these technical developments, regulatory frameworks for pAb-based therapeutics are evolving, emphasizing the need for standardized analytical criteria to ensure safety, efficacy, and batch-to-batch consistency. In our view, by integrating new analytical capabilities with clear regulatory expectations, pAbs can be more effectively developed as therapeutic agents, complementing mAbs and expanding the range of immunoglobulin-based interventions in clinical practice.

Для цитирования: Kumar Sunil, Tini Aurora, Tengattini Sara, Rinaldi Francesca, Calleri Enrica, Massolini Gabriella, Temporini Caterina. Polyclonal Antibody Therapeutics: Analytical Innovations and Regulatory Perspectives for Addressing Heterogeneity Challenges.. Analytical chemistry. 2026. DOI: 10.1021/acs.analchem.5c06531.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.